In this article, we will list the 5 Most Oversold Strong Buy-Rated Stocks to Invest In. Please visit 8 Most Oversold Strong Buy-Rated Stocks to Invest In if you would like to see the extended list and the methodology behind it.
5. Insulet Corporation (NASDAQ:PODD)
On March 30, 2026, Insulet Corporation (NASDAQ:PODD) announced the appointment of Mike Panos as Executive Vice President and Chief Commercial Officer, effective immediately. Mike Panos will lead the company’s global commercial organization and report to President and Chief Executive Officer Ashley McEvoy, while also joining the Executive Leadership Team. Mike Panos brings 30 years of commercial leadership experience in medical technology, most recently serving as Leader, Sales Excellence at Stryker Corporation.
On March 13, 2026, Truist said shares of Insulet were trading lower following an 8-K disclosure of a Voluntary Device Correction for certain Omnipod 5 lots. Truist noted the issue could serve as a negative headline amid increasing competition, but said the impact should be manageable, citing 18 reported serious adverse events with no deaths and no change to guidance. Truist added that remediation costs will be excluded from non-GAAP results and maintained a Buy rating with a price target, while noting the stock reaction appears worse than the likely financial or market share impact.
Earlier in March, Insulet presented new clinical data supporting the development of its fully closed-loop automated insulin delivery system for type 2 diabetes at the ATTD conference in Barcelona. The EVOLUTION 2C feasibility study included 24 participants and showed time in range increased to 68%, a 24% improvement over standard injection therapy, with time below range at 0.14%. The study reported no severe hypoglycemia or diabetic ketoacidosis events, with improved glycemic outcomes observed across a diverse participant group.
Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
4. Progress Software Corporation (NASDAQ:PRGS)
On April 1, 2026, Citi analyst Fatima Boolani lowered the price target on Progress Software Corporation (NASDAQ:PRGS) to $46 from $60 previously and maintained a Buy rating on the shares.
On March 31, 2026, Oppenheimer analyst Ittai Kidron lowered the price target on Progress Software Corporation (NASDAQ:PRGS) to $57 from $70 previously to reflect industry multiple compression while keeping an Outperform rating. Ittai Kidron noted the company delivered a solid Q1, with revenue and earnings ahead of expectations, supported by expense discipline and operating margin upside.
On March 30, 2026, Progress Software Corporation (NASDAQ:PRGS) reported Q1 non-GAAP EPS of $1.60, above the $1.57 consensus estimate, with revenue of $248M compared to the $246.4M consensus. The company expects FY26 non-GAAP EPS of $5.91-$6.03 versus the $5.88 consensus and sees revenue of $988M-$1B compared to the $993.34M consensus.
Progress Software Corporation (NASDAQ:PRGS) develops and manages AI-powered applications and digital experiences.
3. Valneva SE (NASDAQ:VALN)
On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405. Jefferies said that the stock reaction reflects a headline miss on statistical significance, noting 73.2% efficacy at 28 days post-dose did not meet the required threshold on the lower bound of the confidence interval. The firm has added that the weakness presents a buying opportunity on the shares of Valneva SE (NASDAQ:VALN) with a path to approval still intact.
On the same day, Pfizer and Valneva SE (NASDAQ:VALN) have announced the topline results from the Phase 3 VALOR trial showing 73.2% efficacy from 28 days post-dose and 74.8% efficacy from one day post-dose in reducing confirmed Lyme disease cases versus placebo. Pfizer and Valneva SE (NASDAQ:VALN) have said that fewer cases than expected were recorded, and the first pre-specified statistical criterion was not met, but noted the second analysis showed a confidence interval lower bound above 20, supporting plans for regulatory submissions.
Valneva SE (NASDAQ:VALN) develops, manufactures, and commercializes vaccines for infectious diseases.
2. Vital Farms, Inc. (NASDAQ:VITL)
On April 2, 2026, Craig-Hallum lowered the price target on Vital Farms, Inc. (NASDAQ:VITL) to $20 from $55 previously and maintained a Buy rating on the shares. Craig-Hallum said that the stock has been under pressure following lowered fiscal 2026 guidance in February and “volatile and at times lackluster” volume growth based on scanner data, while also pointing to a more competitive environment, with competing brands offering “extreme discounts,” including 50% off and buy-one-get-one deals.
On March 27, 2026, Telsey Advisory lowered its price target on Vital Farms, Inc. (NASDAQ:VITL) to $26 from $35 previously and maintained an Outperform rating on the shares, citing reduced estimates for Q1 and FY26 due to macro uncertainty and near-term industry changes. Telsey Advisory said it still expects double-digit sales growth in 2026 and sees multi-year visibility beyond near-term trends.
On March 2, 2026, Mizuho also lowered its price target on Vital Farms, Inc. (NASDAQ:VITL) to $40 from $48 and maintained an Outperform rating, citing disappointing guidance.
Vital Farms, Inc. (NASDAQ:VITL) packages, markets, and distributes shell eggs, butter, and other food products in the United States.
1. Wingstop Inc. (NASDAQ:WING)
On April 2, 2026, Raymond James upgraded Wingstop Inc. (NASDAQ:WING) to Strong Buy from Outperform with a price target of $240, down from $325. Raymond James said the recent pullback appears overdone following a 44% decline over the past month, noting weaker Q1 comps and lowered 2026 guidance were already anticipated and priced in. The firm added that softer marketing and lack of value messaging may be weighing on comps, but described these issues as fixable.
On April 1, 2026, Piper Sandler upgraded Wingstop to Overweight from Neutral with a price target of $190, down from $283. Piper Sandler said the stock’s risk/reward is more attractive after recent underperformance and expects consensus estimates to be revised lower, but noted this is already reflected in the share price.
Last month, Wingstop announced a $300M increase to its share repurchase authorization, continuing its existing program under which it has invested nearly $700M since August 2023 and repurchased about 2.6M shares. The company repurchased just over 1.2M shares in 2025 and has approximately $53.4M remaining under the current authorization.
Wingstop Inc. (NASDAQ:WING) franchises and operates restaurants under the Wingstop brand across multiple international markets.
While we acknowledge the potential of WING to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WING and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 7 Heavily-Battered Consumer Stocks That Could Triple by 2027 and 10 Best 52-Week Low NYSE Stocks to Buy Now
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
